Clicky

Mymetics Corp(MYMX)

Description: Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.


Keywords: Medicine Infectious Diseases Vaccines Influenza Vaccination Lipid HIV/Aids Antigen Deficiency Immunodeficiency Malaria Herpes Influenza Vaccine Herpes Simplex Sexually Transmitted Diseases And Infections Herpes Simplex Virus Influenza Virus Immune Deficiency Syndrome Immune Deficiency Membrane Protein Membrane Proteins Mym Simplex

Home Page: www.mymetics.com

BiopOle Center
Epalinges, 1066
Switzerland
Phone: 41 21 653 4535


Officers

Name Title
Mr. Ronald Kempers CEO, COO, Pres & CFO
Dr. Sylvain Fleury Chief Scientific Officer
Dr. Antonius Johanne Stegmann Head of R&D and Chief Scientific Officer of Mymetics BV
Mr. Mario Amacker Ph.D. Head of Quality & Manufacturing

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 12.1723
IPO Date: 1995-03-30
Fiscal Year End: December
Full Time Employees: 9
Back to stocks